Compare Nutrien Ltd (NTR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs 10X Genomics Inc — how do they compare? Nutrien Ltd trades at $70.2 (market cap $33.31B), while 10X Genomics Inc trades at $84.56 (market cap $10.07B). The key difference: Nutrien Ltd is far larger — about 3.3× 10X Genomics Inc's market cap, and Nutrien Ltd pays a 3.15% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and 10X Genomics Inc for 92 Days on average.
| NTR | TXG | |
|---|---|---|
Market Cap | $33.31B | $10.07B |
Volume | 1,330,729 | 5,657,286 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $97.74 |
52-Week Low | $53.64 | $11.48 |
Typical Hold Time | 59 Days | 92 Days |
Enterprise Value | $45.11B | $9.59B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.97, down 1.73% today, with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation at P/E of 14.14. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations, while analyst consensus remains bullish with $76.14 price target.
NTR presents value opportunity with reasonable valuation and strong agricultural market positioning, though faces headwinds from fertilizer price volatility and competitive pressures. The stock's current discount to analyst targets and oversold technical condition suggest potential upside, but investors should monitor input cost trends and global fertilizer demand dynamics closely.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
